Sabine Scholl-Bürgi1, Daniela Karall2, Thomas Zöggeler1, Katharina Stock3, Monika Jörg-Streller1, Johannes Spenger4, Vassiliki Konstantopoulou5, Miriam Hufgard-Leitner6. 1. Department of Pediatrics I (Inherited Metabolic Disorders), Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. 2. Department of Pediatrics I (Inherited Metabolic Disorders), Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. daniela.karall@i-med.ac.at. 3. Department of Pediatrics III (Cardiology), Medical University of Innsbruck, Innsbruck, Austria. 4. University Children's Hospital, Salzburger Landeskliniken (SALK) and Paracelsus Medical University (PMU), Salzburg, Austria. 5. Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria. 6. Department of Internal Medicine III (Clinical Division of Endocrinology and Inherited Metabolic Disorders), Medical University of Vienna, Vienna, Austria.
Abstract
BACKGROUND: Long-chain fatty acid oxidation disorders (LC-FAOD) are a group of rare inborn errors of metabolism with autosomal recessive inheritance that may cause life-threatening events. Treatment with triheptanoin, a synthetic seven-carbon fatty acid triglyceride compound with an anaplerotic effect, seems beneficial, but clinical experience is limited. We report our long-term experience in an Austrian cohort of LC-FAOD patients. METHODS: We retrospectively assessed clinical outcome and total hospitalization days per year before and after start with triheptanoin by reviewing medical records of 12 Austrian LC-FAOD patients RESULTS: For 12 Austrian LC-FAOD patients at three metabolic centers, triheptanoin was started shortly after birth in 3/12, and between 7.34 and 353.3 (median 44.5; mean 81.1) months of age in 9/12 patients. For 11 pediatric patients, mean duration of triheptanoin intake was 5.3 (median 3.9, range 1.2-15.7) years, 10/11 pediatric patients have an ongoing intake of triheptanoin. One patient quit therapy due to reported side effects. Total hospitalization days per year compared to before triheptanoin treatment decreased by 82.3% from 27.1 (range 11-65) days per year to 4.8 (range 0-13) days per year, and hospitalization days in the one year pre- compared to the one year post-triheptanoin decreased by 69.8% from 27.1 (range 4-75) days to 8.2 (range 0-25) days. All patients are in good clinical condition, show normal psychomotor development and no impairment in daily life activities. CONCLUSION: In this retrospective observational study in an Austrian LC-FAOD cohort, triheptanoin data show improvement in disease course. Triheptanoin appears to be a safe and beneficial treatment option in LC-FAOD. For further clarification, additional prospective randomized controlled trials are needed.
BACKGROUND:Long-chain fatty acid oxidation disorders (LC-FAOD) are a group of rare inborn errors of metabolism with autosomal recessive inheritance that may cause life-threatening events. Treatment with triheptanoin, a synthetic seven-carbon fatty acidtriglyceride compound with an anaplerotic effect, seems beneficial, but clinical experience is limited. We report our long-term experience in an Austrian cohort of LC-FAOD patients. METHODS: We retrospectively assessed clinical outcome and total hospitalization days per year before and after start with triheptanoin by reviewing medical records of 12 Austrian LC-FAOD patients RESULTS: For 12 Austrian LC-FAOD patients at three metabolic centers, triheptanoin was started shortly after birth in 3/12, and between 7.34 and 353.3 (median 44.5; mean 81.1) months of age in 9/12 patients. For 11 pediatric patients, mean duration of triheptanoin intake was 5.3 (median 3.9, range 1.2-15.7) years, 10/11 pediatric patients have an ongoing intake of triheptanoin. One patient quit therapy due to reported side effects. Total hospitalization days per year compared to before triheptanoin treatment decreased by 82.3% from 27.1 (range 11-65) days per year to 4.8 (range 0-13) days per year, and hospitalization days in the one year pre- compared to the one year post-triheptanoin decreased by 69.8% from 27.1 (range 4-75) days to 8.2 (range 0-25) days. All patients are in good clinical condition, show normal psychomotor development and no impairment in daily life activities. CONCLUSION: In this retrospective observational study in an Austrian LC-FAOD cohort, triheptanoin data show improvement in disease course. Triheptanoin appears to be a safe and beneficial treatment option in LC-FAOD. For further clarification, additional prospective randomized controlled trials are needed.
Authors: U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel Journal: J Inherit Metab Dis Date: 2009-04-28 Impact factor: 4.982
Authors: J Vockley; B Burton; G T Berry; N Longo; J Phillips; A Sanchez-Valle; P Tanpaiboon; S Grunewald; E Murphy; R Humphrey; J Mayhew; A Bowden; L Zhang; J Cataldo; D L Marsden; E Kakkis Journal: Mol Genet Metab Date: 2017-02-07 Impact factor: 4.797
Authors: Isaac Marin-Valencia; Levi B Good; Qian Ma; Craig R Malloy; Juan M Pascual Journal: J Cereb Blood Flow Metab Date: 2012-10-17 Impact factor: 6.200
Authors: U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel Journal: J Inherit Metab Dis Date: 2009-04-29 Impact factor: 4.982
Authors: Marit Schwantje; Sabine A Fuchs; Lonneke de Boer; Annet M Bosch; Inge Cuppen; Eugenie Dekkers; Terry G J Derks; Sacha Ferdinandusse; Lodewijk Ijlst; Riekelt H Houtkooper; Rose Maase; W Ludo van der Pol; Maaike C de Vries; Rendelien K Verschoof-Puite; Ronald J A Wanders; Monique Williams; Frits Wijburg; Gepke Visser Journal: J Inherit Metab Dis Date: 2022-04-19 Impact factor: 4.750